BRAF and cutaneous melanoma: Approximately 40% of cutaneous melanoma patients have tumors with an activating mutation in the BRAF gene (BRAF V600E/K), which activates the MAPK pathway via a phosphorylation cascade that activates MEK and ERK [2].